Current News
Accera, Inc., announced data which showed that augmentation with ketone bodies significantly improved cognitive function in Alzheimer's disease (AD) patients. Data to be presented at the
25th International Conference of Alzheimer's Disease International March 10-13, 2010
Accera, Inc. to Present at the 3rd Annual European Life Science CEO Forum for Partnering & Investing
Accera, Inc., announced today that it will present at the 3rd Annual European Life Science CEO Forum for Partnering
& Investing February 11-12, 2010 at the ConventionPoint in Zurich, Switzerland.
November is Alzheimer’s Awareness Month. Every 70 seconds someone in the United States develops Alzheimer’s disease, and the number of cases is expected to double every 20 years. This devastating and progressive disease not only affects patients, but also takes a physical toll on the friends and family members who care for them.
Accera, Inc., announced today the culmination of its "Lost & Found" campaign, an online educational initiative whereby each visit to www.lostandfoundcampaign.com prompted a donation by Accera to support the Alzheimer's Foundation of America (AFA).
Accera, Inc., announced today announced today that it will present at Lazard Capital Markets 6th Annual Healthcare Conference November 17-18, 2009 at the St. Regis Hotel in New York.
Accera, Inc., announced today it has been elected as The Colorado Bioscience Association's 2009 “Company of the Year” Award recipient.
Accera, Inc., announced today that it will present at the UBS Global Life Sciences Conference September 21-23, 2009 in New York.
Accera, Inc., announced today publication of a scientific paper in the peer-reviewed journal Nutrition & Metabolism. The paper, entitled “Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial” suggests that daily administration of AC-1202 (Axona™) can help improve cognition and memory in patients with mild-to-moderate Alzheimer’s disease (AD).
Accera, Inc., announced today the launch of its “Lost & Found” campaign, an on-line initiative whereby each visit to
www.lostandfoundcampaign.com prompts a $1
donation by Accera to support the Alzheimer’s Foundation of America (AFA).
Accera, Inc. announced that Gunnar Weikert,
M.D., Ph.D., has been elected to its Board of Directors.
Dr. Weikert is the Chairman, CEO and Founder of Inventages
Venture Capital, and replaces Dr. Robert Schier as an
investor director.
Accera, Inc., a biotechnology company
delivering breakthrough therapies in central nervous
system diseases, today announced further evidence for
genetic interactions impacting the efficacy of the ketogenic
compound AC-1202 (Axona™) in Alzheimer’s disease.
Accera, Inc., a biotechnology company
delivering breakthrough therapies in central nervous
system (CNS) diseases, announced the formation of a
wholly-owned subsidiary, Neuera Pharmaceuticals, Inc.
that will focus on the discovery and development of
small molecule drugs for neurology.
Accera, Inc., a biotechnology company
delivering breakthrough therapies in central nervous
system (CNS) disorders, today announced that the company
will be participating at the 2nd Annual BIO Venture
Conference and the C21 Bioventures Conference.
Accera, Inc., a biotechnology company
delivering breakthrough therapies in central nervous
system (CNS) diseases, announced today that Thomas Werner,
Ph.D. has been elected to its board of directors.
Accera, Inc., a biotechnology company
delivering breakthrough therapies in central nervous
system (CNS) diseases, today launched Axona® in
the United States for Alzheimer’s disease (AD). Axona
is a first-in-class medical food for the clinical dietary
management of the metabolic processes associated with
mild-to-moderate Alzheimer’s. Dispensed by prescription,
it targets the metabolic deficiencies and imbalances
associated with AD by providing an alternative energy
source for brain cells.
Accera, Inc., a biotechnology company
delivering breakthrough therapies in central nervous
system (CNS) diseases, announced today it is a SILVER
level sponsor of the 2009 International Conference on
Alzheimer’s Disease (ICAD). The annual conference, put
on by the Alzheimer’s Association, is the world’s leading
forum on dementia research.
Andrew Mielach
Tiberend Strategic Advisors, Inc.
ph: 212.827.0020
email: amielach@tiberendstrategicadvisors.com
For Axona PR:
Kelly McKenna
MS&L Worldwide
ph: 415.293.2808
email: kelly.mckenna@mslworldwide.com